Concepts (175)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Ophthalmology | 13 | 2020 | 37 | 3.890 |
Why?
|
| Internship and Residency | 14 | 2020 | 263 | 3.440 |
Why?
|
| Cataract Extraction | 9 | 2021 | 29 | 3.230 |
Why?
|
| Cataract | 7 | 2022 | 29 | 2.100 |
Why?
|
| Clinical Competence | 10 | 2020 | 249 | 1.670 |
Why?
|
| Curriculum | 6 | 2018 | 307 | 1.520 |
Why?
|
| Phacoemulsification | 6 | 2021 | 21 | 1.290 |
Why?
|
| Education, Medical, Graduate | 7 | 2020 | 119 | 1.210 |
Why?
|
| Academic Medical Centers | 2 | 2026 | 79 | 0.950 |
Why?
|
| Organizational Culture | 1 | 2026 | 27 | 0.940 |
Why?
|
| Delivery of Health Care | 2 | 2026 | 121 | 0.890 |
Why?
|
| Quality Improvement | 1 | 2026 | 130 | 0.870 |
Why?
|
| Glaucoma | 2 | 2022 | 53 | 0.840 |
Why?
|
| Teaching | 3 | 2015 | 84 | 0.820 |
Why?
|
| Lens Implantation, Intraocular | 6 | 2020 | 20 | 0.770 |
Why?
|
| Ophthalmologic Surgical Procedures | 4 | 2017 | 24 | 0.700 |
Why?
|
| Postoperative Complications | 5 | 2019 | 643 | 0.690 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2022 | 177 | 0.660 |
Why?
|
| Humans | 38 | 2026 | 29211 | 0.660 |
Why?
|
| Intraoperative Complications | 3 | 2022 | 47 | 0.630 |
Why?
|
| Education | 2 | 2017 | 33 | 0.630 |
Why?
|
| Postoperative Care | 1 | 2019 | 68 | 0.590 |
Why?
|
| Diabetes Mellitus, Type 2 | 2 | 2022 | 346 | 0.580 |
Why?
|
| Eye Injuries, Penetrating | 4 | 2011 | 4 | 0.560 |
Why?
|
| Retrospective Studies | 16 | 2022 | 2662 | 0.550 |
Why?
|
| Contact Lenses | 1 | 2017 | 6 | 0.530 |
Why?
|
| Students, Medical | 1 | 2019 | 102 | 0.530 |
Why?
|
| Social Media | 1 | 2019 | 67 | 0.530 |
Why?
|
| Interdisciplinary Communication | 1 | 2017 | 19 | 0.530 |
Why?
|
| Skull Base Neoplasms | 1 | 2017 | 22 | 0.520 |
Why?
|
| Keratitis | 1 | 2017 | 31 | 0.520 |
Why?
|
| Lenses, Intraocular | 4 | 2021 | 20 | 0.470 |
Why?
|
| Laser Therapy | 1 | 2015 | 30 | 0.430 |
Why?
|
| Education, Medical, Continuing | 1 | 2015 | 35 | 0.430 |
Why?
|
| Perioperative Care | 5 | 2021 | 35 | 0.390 |
Why?
|
| General Surgery | 1 | 2013 | 63 | 0.370 |
Why?
|
| Aged, 80 and over | 10 | 2021 | 2070 | 0.360 |
Why?
|
| Female | 18 | 2022 | 15825 | 0.350 |
Why?
|
| Visual Acuity | 6 | 2016 | 120 | 0.350 |
Why?
|
| Sclera | 1 | 2011 | 11 | 0.340 |
Why?
|
| Surgeons | 2 | 2022 | 50 | 0.340 |
Why?
|
| Surgical Wound Dehiscence | 1 | 2011 | 16 | 0.340 |
Why?
|
| Surveys and Questionnaires | 3 | 2019 | 1020 | 0.310 |
Why?
|
| Cornea | 2 | 2021 | 72 | 0.290 |
Why?
|
| Practice Guidelines as Topic | 2 | 2022 | 250 | 0.290 |
Why?
|
| Male | 17 | 2022 | 14126 | 0.290 |
Why?
|
| Aged | 12 | 2021 | 5648 | 0.280 |
Why?
|
| Adult | 13 | 2021 | 8130 | 0.270 |
Why?
|
| Hyphema | 1 | 2007 | 2 | 0.260 |
Why?
|
| Anterior Chamber | 1 | 2007 | 6 | 0.260 |
Why?
|
| Eye Injuries | 1 | 2007 | 11 | 0.260 |
Why?
|
| Middle Aged | 10 | 2019 | 7495 | 0.260 |
Why?
|
| Massachusetts | 4 | 2021 | 19 | 0.250 |
Why?
|
| Wounds, Nonpenetrating | 1 | 2007 | 52 | 0.250 |
Why?
|
| United States | 4 | 2022 | 2270 | 0.250 |
Why?
|
| Pediatrics | 1 | 2008 | 117 | 0.240 |
Why?
|
| Orbit | 1 | 2006 | 12 | 0.240 |
Why?
|
| Orbital Neoplasms | 1 | 2006 | 11 | 0.240 |
Why?
|
| Nerve Compression Syndromes | 1 | 2006 | 13 | 0.240 |
Why?
|
| Optic Nerve Diseases | 1 | 2006 | 16 | 0.240 |
Why?
|
| Cellulitis | 1 | 2006 | 7 | 0.240 |
Why?
|
| Needs Assessment | 2 | 2017 | 57 | 0.240 |
Why?
|
| Orbital Diseases | 1 | 2006 | 11 | 0.230 |
Why?
|
| Leadership | 1 | 2026 | 58 | 0.230 |
Why?
|
| Educational Measurement | 3 | 2017 | 142 | 0.230 |
Why?
|
| Decompression, Surgical | 1 | 2006 | 81 | 0.230 |
Why?
|
| Incidence | 4 | 2019 | 581 | 0.220 |
Why?
|
| Communication | 2 | 2017 | 185 | 0.210 |
Why?
|
| Prospective Studies | 4 | 2019 | 1288 | 0.190 |
Why?
|
| Oklahoma | 1 | 2026 | 1063 | 0.180 |
Why?
|
| Cross-Sectional Studies | 2 | 2022 | 1013 | 0.180 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2002 | 97 | 0.180 |
Why?
|
| Receptors, Cell Surface | 1 | 2002 | 114 | 0.180 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2002 | 140 | 0.170 |
Why?
|
| Astigmatism | 1 | 2021 | 11 | 0.170 |
Why?
|
| Primary Health Care | 1 | 2022 | 169 | 0.160 |
Why?
|
| Operating Rooms | 1 | 2020 | 21 | 0.150 |
Why?
|
| Operative Time | 1 | 2020 | 41 | 0.150 |
Why?
|
| Trauma Severity Indices | 2 | 2011 | 37 | 0.150 |
Why?
|
| Infant | 4 | 2011 | 1067 | 0.150 |
Why?
|
| Information Storage and Retrieval | 1 | 2019 | 31 | 0.140 |
Why?
|
| Child, Preschool | 4 | 2011 | 1215 | 0.140 |
Why?
|
| Iris | 1 | 2018 | 8 | 0.140 |
Why?
|
| Refraction, Ocular | 2 | 2021 | 26 | 0.140 |
Why?
|
| Computer-Assisted Instruction | 1 | 2019 | 33 | 0.140 |
Why?
|
| Retinopathy of Prematurity | 1 | 2019 | 40 | 0.140 |
Why?
|
| Career Choice | 1 | 2019 | 53 | 0.140 |
Why?
|
| Telepathology | 1 | 2018 | 4 | 0.140 |
Why?
|
| Photography | 1 | 2018 | 19 | 0.140 |
Why?
|
| Diagnostic Techniques, Ophthalmological | 1 | 2018 | 7 | 0.140 |
Why?
|
| Physical Examination | 1 | 2018 | 53 | 0.130 |
Why?
|
| Skull Base | 1 | 2017 | 35 | 0.130 |
Why?
|
| Prosthesis Design | 1 | 2017 | 88 | 0.130 |
Why?
|
| Risk Assessment | 1 | 2019 | 632 | 0.130 |
Why?
|
| Intraocular Pressure | 2 | 2018 | 62 | 0.120 |
Why?
|
| Diabetic Retinopathy | 1 | 2018 | 112 | 0.120 |
Why?
|
| Simulation Training | 1 | 2017 | 38 | 0.120 |
Why?
|
| Child | 4 | 2011 | 2354 | 0.120 |
Why?
|
| Filtering Surgery | 1 | 2015 | 9 | 0.110 |
Why?
|
| Pilot Projects | 1 | 2017 | 467 | 0.110 |
Why?
|
| Boston | 1 | 2015 | 7 | 0.110 |
Why?
|
| Posterior Capsulotomy | 1 | 2015 | 1 | 0.110 |
Why?
|
| Telemedicine | 1 | 2018 | 228 | 0.110 |
Why?
|
| Follow-Up Studies | 3 | 2021 | 1033 | 0.100 |
Why?
|
| Pseudophakia | 1 | 2013 | 7 | 0.100 |
Why?
|
| Coffee | 1 | 2012 | 5 | 0.090 |
Why?
|
| Glaucoma, Open-Angle | 1 | 2012 | 23 | 0.090 |
Why?
|
| Caffeine | 1 | 2012 | 39 | 0.090 |
Why?
|
| Central Nervous System Stimulants | 1 | 2012 | 33 | 0.090 |
Why?
|
| Blindness | 2 | 2009 | 34 | 0.090 |
Why?
|
| Age Distribution | 1 | 2011 | 75 | 0.080 |
Why?
|
| Sex Distribution | 1 | 2011 | 78 | 0.080 |
Why?
|
| Blood Pressure | 1 | 2012 | 358 | 0.080 |
Why?
|
| Heart Rate | 1 | 2012 | 383 | 0.080 |
Why?
|
| Eye Enucleation | 1 | 2009 | 1 | 0.070 |
Why?
|
| Vitrectomy | 1 | 2009 | 8 | 0.070 |
Why?
|
| Adolescent | 3 | 2011 | 3255 | 0.070 |
Why?
|
| Retinal Diseases | 1 | 2009 | 47 | 0.070 |
Why?
|
| Inflammation | 2 | 2018 | 672 | 0.070 |
Why?
|
| Blood | 1 | 2007 | 34 | 0.060 |
Why?
|
| Eye Infections, Bacterial | 1 | 2009 | 129 | 0.060 |
Why?
|
| Endophthalmitis | 1 | 2009 | 125 | 0.060 |
Why?
|
| Color Perception | 1 | 2006 | 3 | 0.060 |
Why?
|
| Postoperative Period | 2 | 2018 | 68 | 0.060 |
Why?
|
| Visual Fields | 1 | 2006 | 35 | 0.060 |
Why?
|
| Ocular Hypertension | 2 | 2018 | 11 | 0.060 |
Why?
|
| Retina | 1 | 2009 | 446 | 0.060 |
Why?
|
| Benchmarking | 2 | 2016 | 33 | 0.050 |
Why?
|
| Diagnosis, Differential | 1 | 2006 | 382 | 0.050 |
Why?
|
| Young Adult | 1 | 2011 | 2877 | 0.050 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2006 | 484 | 0.050 |
Why?
|
| Receptors, Leptin | 1 | 2002 | 6 | 0.050 |
Why?
|
| Amino Acid Motifs | 1 | 2002 | 66 | 0.050 |
Why?
|
| Tyrosine | 1 | 2002 | 92 | 0.050 |
Why?
|
| Janus Kinase 2 | 1 | 2002 | 36 | 0.050 |
Why?
|
| Protein Isoforms | 1 | 2002 | 119 | 0.050 |
Why?
|
| Enzyme Activation | 1 | 2002 | 267 | 0.040 |
Why?
|
| STAT3 Transcription Factor | 1 | 2002 | 97 | 0.040 |
Why?
|
| Trans-Activators | 1 | 2002 | 118 | 0.040 |
Why?
|
| Phosphorylation | 1 | 2002 | 586 | 0.040 |
Why?
|
| Amino Acid Sequence | 1 | 2002 | 697 | 0.040 |
Why?
|
| Molecular Sequence Data | 1 | 2002 | 1057 | 0.040 |
Why?
|
| Biometry | 1 | 2020 | 23 | 0.040 |
Why?
|
| Healthcare Disparities | 1 | 2021 | 99 | 0.040 |
Why?
|
| Eye, Artificial | 1 | 2019 | 1 | 0.040 |
Why?
|
| Feedback | 1 | 2019 | 32 | 0.040 |
Why?
|
| DNA-Binding Proteins | 1 | 2002 | 490 | 0.040 |
Why?
|
| Antihypertensive Agents | 1 | 2018 | 56 | 0.030 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2018 | 79 | 0.030 |
Why?
|
| Urban Population | 1 | 2018 | 97 | 0.030 |
Why?
|
| Task Performance and Analysis | 1 | 2017 | 43 | 0.030 |
Why?
|
| Motor Skills | 1 | 2017 | 34 | 0.030 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2019 | 317 | 0.030 |
Why?
|
| Reproducibility of Results | 1 | 2018 | 794 | 0.030 |
Why?
|
| Cohort Studies | 1 | 2017 | 903 | 0.030 |
Why?
|
| Hospitals, Teaching | 1 | 2013 | 26 | 0.030 |
Why?
|
| Mice | 1 | 2002 | 4870 | 0.020 |
Why?
|
| Tonometry, Ocular | 1 | 2012 | 9 | 0.020 |
Why?
|
| Gonioscopy | 1 | 2012 | 7 | 0.020 |
Why?
|
| Beverages | 1 | 2012 | 24 | 0.020 |
Why?
|
| Societies, Medical | 1 | 2012 | 93 | 0.020 |
Why?
|
| ROC Curve | 1 | 2012 | 144 | 0.020 |
Why?
|
| Cross-Over Studies | 1 | 2012 | 139 | 0.020 |
Why?
|
| Double-Blind Method | 1 | 2012 | 426 | 0.020 |
Why?
|
| Eye Evisceration | 1 | 2009 | 1 | 0.020 |
Why?
|
| Infusions, Intravenous | 1 | 2009 | 102 | 0.020 |
Why?
|
| Animals | 1 | 2002 | 10806 | 0.020 |
Why?
|
| Recovery of Function | 1 | 2009 | 123 | 0.020 |
Why?
|
| Combined Modality Therapy | 1 | 2009 | 303 | 0.020 |
Why?
|
| Treatment Outcome | 1 | 2013 | 2442 | 0.020 |
Why?
|
| Prognosis | 1 | 2009 | 817 | 0.020 |
Why?
|
| Pain | 1 | 2009 | 258 | 0.020 |
Why?
|
| Time Factors | 1 | 2009 | 1619 | 0.010 |
Why?
|
| Anti-Bacterial Agents | 1 | 2009 | 540 | 0.010 |
Why?
|
| Risk Factors | 1 | 2009 | 2144 | 0.010 |
Why?
|